DB-1310 by Duality Biologics (Shanghai) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Johnson & Johnson sues Biden administration over payment terms for 340B hospitals

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some hospitals that participate in a

November 12, 2024

Biden’s top antitrust official calls for breaking up powerful health care companies

Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses

January 10, 2025

Boehringer, Gubra stop work on obesity drug; Galapagos restarts CAR-T study

Plus, news about Alnylam, Hutchmed, Wave Life Sciences and Matinas BioPharma: Boehringer Ingelheim ends work with Gubra on obesity drug: The German drugmaker Sign up

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.